NASDAQ:NAKA KindlyMD (NAKA) Stock Price, News & Analysis $9.57 +2.07 (+27.60%) As of 08/8/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock About KindlyMD Stock (NASDAQ:NAKA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get KindlyMD alerts:Sign Up Key Stats Today's Range$7.34▼$10.1750-Day Range$6.35▼$18.3452-Week Range$0.65▼$34.77Volume654,338 shsAverage Volume301,723 shsMarket Capitalization$72.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT. Read More Receive NAKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KindlyMD and its competitors with MarketBeat's FREE daily newsletter. Email Address NAKA Stock News HeadlinesKindlyMD and Nakamoto Announce the Filing of the Definitive Information Statement in Connection with Proposed MergerJuly 22, 2025 | businesswire.comYZi Labs Announces Support for 10X Capital's BNB Treasury Company in the U.S.July 9, 2025 | globenewswire.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!). | Weiss Ratings (Ad)KindlyMD and Nakamoto Announce an Additional $51.5 Million In PIPE Financing To Support Bitcoin Treasury EffortsJune 20, 2025 | businesswire.comNakamoto Holdings Appoints Tyler Evans as Chief Investment Officer to Lead Bitcoin-Native Capital DeploymentJune 18, 2025 | businesswire.comNakamoto Holdings to Participate in ICR Conference Spotlight SeriesJune 17, 2025 | businesswire.comSee More Headlines NAKA Stock Analysis - Frequently Asked Questions How have NAKA shares performed this year? KindlyMD's stock was trading at $11.60 on January 1st, 2025. Since then, NAKA stock has decreased by 17.5% and is now trading at $9.57. How were KindlyMD's earnings last quarter? KindlyMD, Inc. (NASDAQ:NAKA) issued its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.34) EPS for the quarter. The business had revenue of $0.41 million for the quarter. KindlyMD had a negative net margin of 244.00% and a negative trailing twelve-month return on equity of 131.09%. How do I buy shares of KindlyMD? Shares of NAKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/05/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:NAKA CIK1946573 WebN/A Phone(385) 388-8220FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.62 million Net Margins-244.00% Pretax Margin-244.00% Return on Equity-131.09% Return on Assets-106.04% Debt Debt-to-Equity RatioN/A Current Ratio13.00 Quick Ratio2.30 Sales & Book Value Annual Sales$2.24 million Price / Sales32.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book8.55Miscellaneous Outstanding Shares7,305,000Free Float4,325,000Market Cap$73.71 million OptionableN/A Beta34.35 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:NAKA) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KindlyMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KindlyMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.